16 pages | 8.5 x 11
In 2003, the Boston University Medical Center (BUMC) was awarded a $128 million grant from the National Institutes of Health to build one of two high- and maximum- containment laboratory facilities for research on biological pathogens. The National Emerging Infectious Disease Laboratories (NEIDL) are meant to support the National Institute of Allergy and Infectious Diseases and biodefense research agenda, conducting research to develop new approaches to treating, preventing, and diagnosing a variety of viral diseases. Diseases and agents to be studied include viruses and bacteria that occur naturally and cause infections or that could be used in deliberate attacks. Continuing Assistance to the National Institutes of Health on Preparation of Additional Risk Assessments for the Boston University NEIDL, Phase 1 reviews the proposed risk assessment plans associated with operating the NEIDL and provides input on key milestones in the development of supplementary risk assessment.